I’d encourage more work on planning for post-COVID reactions and policy proposals, as well as thinking about how EAs can be in a good position to influence such decisions.
People should be working on funding proposals for Bio-X risk mitigation policies, such as greater international coordination, better health monitoring systems, investment in non-disease specific symptomatic surveillance, and similar. These are likely to be far easier to fund in 3-6 months, as a huge pool of money is allocated to work on fixing the next pandemic.
Mitigation work seems very low on neglectedness.
I’d encourage more work on planning for post-COVID reactions and policy proposals, as well as thinking about how EAs can be in a good position to influence such decisions.
Could you be more specific or provide an example?
People should be working on funding proposals for Bio-X risk mitigation policies, such as greater international coordination, better health monitoring systems, investment in non-disease specific symptomatic surveillance, and similar. These are likely to be far easier to fund in 3-6 months, as a huge pool of money is allocated to work on fixing the next pandemic.